NovaBridge Biosciences shares surge 10.07% premarket after rebranding from I-MAB and strategic transformation to global biotech platform.

NovaBridge Biosciences surged 10.07% in premarket trading following the announcement that I-Mab (IMAB) transitioned to NovaBridge Biosciences (NBP) with trading effective October 30, 2025. The rebranding reflects a strategic transformation to a global biotech platform, including a planned Hong Kong IPO and a new brand and logo. This move, announced six days prior, signals the company’s shift toward expanding its biotech operations and strengthening its market presence, likely boosting investor confidence in its long-term growth prospects.